Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26864557)
Watch
English
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
title
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes
(English)
1 reference
stated in
PubMed
author name string
Kyung Bo Kim
series ordinal
1
1 reference
stated in
Crossref
Craig M. Crews
series ordinal
2
1 reference
stated in
Crossref
language of work or name
English
1 reference
stated in
PubMed
publication date
May 2013
1 reference
stated in
PubMed
published in
Natural Product Reports
1 reference
stated in
PubMed
volume
30
1 reference
stated in
PubMed
issue
5
1 reference
stated in
PubMed
page(s)
600-4
1 reference
stated in
PubMed
cites work
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
21 March 2017
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
21 March 2017
The ubiquitin system
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
21 March 2017
The ubiquitin-proteasome pathway and proteasome inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
21 March 2017
Epoxomicin, a new antitumor agent of microbial origin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
21 March 2017
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Construction of a microbial natural product library for chemical biology studies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Anticancer drug discovery from the marine environment.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Activity-based protein profiling for natural product target discovery
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Chemical genetics-based target identification in drug discovery
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Chemical-genetic approaches for exploring the mode of action of natural products
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
The development of proteasome inhibitors as anticancer drugs
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
The proteasome: a suitable antineoplastic target
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
In the arms of Morpheus the development of morphine for postoperative pain relief
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Structural features of 26S and 20S proteasomes.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Natural products as probes for new drug target identification
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815659
retrieved
28 September 2017
Chemical genetics resulting from a passion for synthetic organic chemistry.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1039%2FC3NP20126K
retrieved
21 January 2018
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1039%2FC3NP20126K
retrieved
21 January 2018
Basic Medical Research Award. The ubiquitin system
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1039%2FC3NP20126K
retrieved
21 January 2018
Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1039%2FC3NP20126K
retrieved
21 January 2018
Marine natural products
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23575525
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Medicinals for the millennia: the historical record
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23575525
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1039/C3NP20126K
0 references
PMC publication ID
3815659
1 reference
stated in
PubMed
PubMed publication ID
23575525
1 reference
stated in
PubMed
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
